These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 10604270)

  • 1. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
    Oh WK; Kantoff PW
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
    Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
    Kreis W; Budman D
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
    Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
    BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?
    Oh WK; Tay MH; Huang J
    Cancer; 2007 Feb; 109(3):477-86. PubMed ID: 17186531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
    Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
    Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future directions in the treatment of androgen-independent prostate cancer.
    Petrylak DP
    Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A; Anastasiadis AG; Feyerabend S; Nagele U; Kuczyk M; Schilling D; Corvin S; Merseburger AS; Stenzl A
    Anticancer Res; 2005; 25(6C):4481-6. PubMed ID: 16334130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Wilding G; Soulie P; Trump D; Das-Gupta A; Small E
    Cancer; 2006 May; 106(9):1917-24. PubMed ID: 16568471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel in prostate cancer.
    Small EJ
    Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
    Harper P
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.